Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Net Income (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Net Income data on record, last reported at -$364.9 million in Q4 2025.

  • For Q4 2025, Net Income fell 87.63% year-over-year to -$364.9 million; the TTM value through Dec 2025 reached -$1.1 billion, down 88.55%, while the annual FY2025 figure was -$1.1 billion, 88.55% down from the prior year.
  • Net Income reached -$364.9 million in Q4 2025 per RVMD's latest filing, down from -$305.2 million in the prior quarter.
  • Across five years, Net Income topped out at -$37.2 million in Q1 2021 and bottomed at -$364.9 million in Q4 2025.
  • Average Net Income over 5 years is -$130.2 million, with a median of -$103.4 million recorded in 2023.
  • Peak YoY movement for Net Income: dropped 8.07% in 2022, then plummeted 185.15% in 2023.
  • A 5-year view of Net Income shows it stood at -$52.7 million in 2021, then dropped by 8.07% to -$56.9 million in 2022, then plummeted by 185.15% to -$162.3 million in 2023, then dropped by 19.8% to -$194.5 million in 2024, then plummeted by 87.63% to -$364.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$364.9 million in Q4 2025, -$305.2 million in Q3 2025, and -$247.8 million in Q2 2025.